CFGS
HRMY icon

Concourse Financial Group Securities’s Harmony Biosciences HRMY Stock Holding History

Concourse Financial Group Securities’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16
Closed -$555 – 2357
2023
Q2 		$563 Buy
16
+13
+433% +$449 ﹤0.01% 2215
2023
Q1 		$97 Sell
3
-9
-75% -$410 ﹤0.01% 2333
2022
Q4 		$661 Buy
+12
New +$660 ﹤0.01% 2219

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Concourse Financial Group Securities's HRMY Position: Q3 2023 in Review

Concourse Financial Group Securities sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 16 shares — an estimated $555 sold.

Concourse Financial Group Securities first reported a position in HRMY in Q4 2022 and held it in 3 quarters. The position peaked at $661 in Q4 2022. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

  • Concourse Financial Group Securities reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
  • Concourse Financial Group Securities sold 16 Harmony Biosciences shares in Q3 2023, an estimated $555.
  • Concourse Financial Group Securities first reported a position in Harmony Biosciences in Q4 2022 and held it in 3 quarters.
  • Concourse Financial Group Securities's Harmony Biosciences position peaked at $661 in Q4 2022.
  • 204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on Concourse Financial Group Securities's 13F filing for Q3 2023, filed 25 Oct 2023.